Surgery and procedures in thalassemia: decisions about the spleen, gallbladder, and other interventions

There is no general thalassemia operation that removes abnormal tissue and thereby corrects the inherited disorder. Patients may need surgery for spleen-related problems, gallstones, dental disease, or an unrelated condition. They may also enter a complex treatment such as hematopoietic cell transplantation. The first question is which specific problem the proposed intervention is intended to solve and what would happen if it were deferred. TIF: Guidelines for Transfusion-Dependent β-Thalassaemia, fifth edition, 2025

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

In thalassemia, splenic enlargement can be associated with red-cell destruction and abnormal blood production. Clinicians consider abdominal discomfort, early fullness after food, blood-cell changes, and transfusion needs when deciding whether the spleen is causing a meaningful problem. The words “enlarged spleen” on an ultrasound report are not sufficient grounds for removal. Aydinok et al.: Other Complications, TIF 2025
Chronic hemolysis can contribute to gallstone disease, but detecting a stone does not automatically require immediate surgery. Pain characteristics, fever, changing jaundice, and imaging help determine whether a gallbladder or bile-duct problem needs intervention. Abdominal symptoms in HbH disease deserve a specific explanation rather than automatic attribution to anemia. Songdej and Teawtrakul: Non-deletional HbH Disease, TIF 2023
Provide the Chinese receiving hospital with the specific proposed intervention, complete thalassemia classification, transfusion and antibody records, previous spleen surgery, and organ complications. Ask whether the relevant surgical, hematology, anesthesia, and blood-bank services can coordinate care. China's official thalassemia collaboration network can help identify institutional contacts, but current acceptance and admission arrangements require direct confirmation. 国家卫生健康委：全国地中海贫血防控协作网，2023 TIF 2025: Multidisciplinary Care and Reference Centres

Quick answer

Full guide

An enlarged spleen needs a clinical explanation

In thalassemia, splenic enlargement can be associated with red-cell destruction and abnormal blood production. Clinicians consider abdominal discomfort, early fullness after food, blood-cell changes, and transfusion needs when deciding whether the spleen is causing a meaningful problem. The words “enlarged spleen” on an ultrasound report are not sufficient grounds for removal. Aydinok et al.: Other Complications, TIF 2025

Bring previous imaging and describe the duration and effect of symptoms. Record whether eating has become difficult or blood requirements have changed. This gives the team a clinical timeline rather than one measurement in isolation. Sudden severe abdominal pain or concerning symptoms after an injury warrant prompt assessment instead of waiting for an elective surgical appointment.

Splenectomy now has a more selective place in care

Splenectomy was historically used more often to increase hemoglobin or reduce transfusions. Recognition of long-term infection and vascular risks has made selection more cautious. Current guidance reserves it mainly for clinically significant splenic enlargement or hypersplenism and generally avoids it in children younger than five. A wish to reduce hospital visits does not establish that surgery offers the best balance. Aydinok et al.: Other Complications, TIF 2025

Discuss whether other care has been optimized, which symptom is expected to improve, and what happens if the benefit is limited. Removing the spleen does not alter the inherited globin abnormality or guarantee an end to transfusions and chelation. A higher postoperative hemoglobin is only one outcome within a longer risk-benefit assessment.

The particular form of HbH disease matters

Typical mild deletional HbH disease usually does not require splenectomy. Selected patients with more symptomatic nondeletional disease may have a discussion about it, with alternatives considered. People who require transfusion from very early childhood or have particularly severe disease may continue to need substantial support after spleen removal. Lal: Deletional Haemoglobin H Disease, TIF 2023 Songdej and Teawtrakul: Non-deletional HbH Disease, TIF 2023

Hb Bart's-related severe alpha-thalassemia has additional considerations involving functional hemoglobin, and splenectomy should not be inferred appropriate merely from the size of the spleen. Provide the full molecular and clinical diagnosis to both surgical and hematology teams. A broad thalassemia label can conceal distinctions that are central to the decision. Amid and Merkeley: Splenomegaly and Splenectomy, TIF alpha guideline 2023

Surgical approaches differ in more than incision size

The choice between laparoscopic and open surgery depends on the patient's anatomy, other conditions, and the surgeon's assessment. A laparoscopic procedure may need conversion to an open approach for safety. Ask about that possibility, postoperative pain management, and the plan for complications; minimally invasive does not mean risk-free. Amid and Merkeley: Splenomegaly and Splenectomy, TIF alpha guideline 2023

Partial splenectomy and splenic embolization should not automatically be presented as established, equally effective, safer substitutes. Long-term evidence is limited in HbH disease. If proposed, clarify the research or structured follow-up context, reasons another intervention might later be needed, and whether the intended remaining function is supported by evidence. Amid and Merkeley: Splenomegaly and Splenectomy, TIF alpha guideline 2023

Infection prevention should be organized before elective spleen removal

Prevention after loss of splenic function includes an appropriate vaccination review, preventive medicines where indicated, and a clear response to fever. Before elective surgery, review immunization records and arrange measures according to the applicable local guidance. Age, previous doses, and individual risks prevent one online vaccine list from replacing a clinical review. Songdej and Fucharoen: Infections and Haemoglobin H Disease, TIF 2023

Know who prescribes preventive medicines, when they will be reassessed, and whom to contact about allergy or intolerance. Vaccination does not remove the need for prompt assessment of fever or significant infection symptoms. A concise portable record of the operation, diagnosis, preventive treatment, and relevant contact details can help an unfamiliar clinician respond appropriately. Songdej and Fucharoen: Infections and Haemoglobin H Disease, TIF 2023

Include clotting risk in the perioperative plan

Thrombosis is a relevant concern after splenectomy in some thalassemia settings, particularly within non-transfusion-dependent disease. Surgery, reduced mobility, and personal history affect prevention decisions. The team must weigh clotting and bleeding risks when choosing measures and their duration. Another patient's aspirin or anticoagulant prescription is not a universal postoperative instruction. TIF 2023: Hypercoagulability and Thrombotic Disease in NTDT

Sudden breathlessness, chest pain, or substantial one-sided limb swelling calls for assessment. A well-healed incision does not exclude an internal complication. At discharge, request separate instructions for wound concerns and systemic symptoms, rather than retaining only the date for suture or wound review.

Gallstone decisions depend on symptoms and the biliary assessment

Chronic hemolysis can contribute to gallstone disease, but detecting a stone does not automatically require immediate surgery. Pain characteristics, fever, changing jaundice, and imaging help determine whether a gallbladder or bile-duct problem needs intervention. Abdominal symptoms in HbH disease deserve a specific explanation rather than automatic attribution to anemia. Songdej and Teawtrakul: Non-deletional HbH Disease, TIF 2023

If splenectomy is already planned and gallstones are present, ask whether treatment of both problems should be considered. The decision should depend on actual need, not a general desire to remove every incidental finding during one admission. An acute biliary problem can also change the urgency and sequence of an originally elective plan. Aydinok et al.: Other Complications, TIF 2025

Give the blood bank time to plan support

Patients with prior transfusions should provide historical antibodies, compatibility requirements, and reaction records. An antibody that is not detectable now may still matter. Before elective surgery, allow hematology, anesthesia, and the blood bank to review whether additional support will be needed. Shah, Wood and Maggio: Blood Transfusion, TIF 2025

Procedures vary in blood loss and physiological demand. One hemoglobin threshold cannot independently establish fitness for every patient and operation. Patients should not arrange an extra transfusion themselves simply for reassurance. Current anemia, cardiac status, the proposed intervention, and expected recovery all contribute to the team's plan.

Cardiac, liver, and endocrine findings can affect anesthesia and recovery

Provide recent cardiac information if myocardial iron, impaired function, or arrhythmia has been identified. Absence of obvious symptoms does not establish that every perioperative issue is resolved. Further testing should be chosen according to the intended procedure and the information already available. TIF 2025: Cardiovascular Disease in TDT

Liver disease, glucose problems, and hormone replacement also deserve explicit attention. Obtain written instructions for chronic medicines around fasting and surgery. Neither stopping all medicines nor taking every product exactly as usual is a sound general rule. The responsible teams should explain which instructions apply to each treatment. TIF 2025: Liver Disease in TDT Casale et al.: Growth Abnormalities, Endocrine, and Bone Disease, TIF 2025

Adjust chelation and other medicines by the actual product and clinical circumstances

Submit prescribed medicines, supplements, and nonprescription products for review. Chelator safety depends partly on kidney, liver, and blood assessments, and illness or reduced intake may affect the plan. If interruption is needed, the clinician should specify its reason and the conditions for restarting rather than leaving an indefinite gap after surgery. Porter, Wood and Coates: Iron Overload and Chelation, TIF 2025

Persistent vomiting, swallowing difficulty, or inability to follow the original regimen should be reported. Do not independently crush tablets or change formulations. Nutrition support should address actual intake and recovery needs while remaining coordinated with treatment, rather than becoming a substitute for it. Fung and Angastiniotis: Nutrition, TIF 2025

Dental procedures also need the relevant medical background

Before extraction or another invasive dental intervention, explain transfusion history, splenectomy, cardiac disease, and current medicines, including treatments affecting bone metabolism. The dentist may need to liaise with hematology about timing, setting, and additional precautions. Thalassemia is neither an automatic prohibition on dental treatment nor a reason to omit the medical review. Kumar and Hattab: Oral and Dental Care, TIF 2025

Regular preventive care can reduce the chance of facing an urgent procedure during a painful infection. If transplantation or another intensive treatment is under consideration, ask how oral assessment should fit into the larger schedule. Investigations should have a defined purpose rather than accumulate simply because a future treatment is possible.

Transplantation is a treatment pathway rather than an ordinary operation

Hematopoietic cell transplantation involves cell-source assessment, conditioning, infusion, recovery, and continuing surveillance. Catheter placement or other supporting procedures may be necessary, but the whole process should not be described as one marrow-replacement operation. Splenectomy or gallbladder removal is not automatically a required preparatory step for every transplant candidate. Pinto et al.: Haematopoietic Cell Transplantation, TIF 2025

Request a staged outline that distinguishes admissions, medicines, collection or infusion, and any supporting surgery. It helps clarify which components are confirmed and which depend on subsequent findings. Families can then plan caregiving around the actual course rather than the date of one procedure.

Arrange postoperative coordination before traveling to China

Provide the Chinese receiving hospital with the specific proposed intervention, complete thalassemia classification, transfusion and antibody records, previous spleen surgery, and organ complications. Ask whether the relevant surgical, hematology, anesthesia, and blood-bank services can coordinate care. China's official thalassemia collaboration network can help identify institutional contacts, but current acceptance and admission arrangements require direct confirmation. 国家卫生健康委：全国地中海贫血防控协作网，2023 TIF 2025: Multidisciplinary Care and Reference Centres

Avoid basing an inflexible return journey only on an estimated wound-review date. Clarify postoperative appointments, possible extended observation, local emergency access, and continuation of vaccines, preventive medicines, and transfusion care after returning home. Wound healing, fitness for travel, and a complete handover are distinct decisions; identify who will make each of them before the intervention takes place.